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RESEARCH ARTICLE
Ubiquitin-specific protease 2a (USP2a) is overexpressed in almost half of human 
prostate cancers and c-Myc is amplified in one third of these tumor types. Transgenic 
MYC expression drives invasive adenocarcinomas in the murine prostate. We show that overexpression 
of USP2a downregulates a set of microRNAs that collectively increase MYC levels by MDM2 deubiqui-
tination and subsequent p53 inactivation. By establishing MYC as a target of miR-34b/c, we demon-
strate that this cluster functions as a tumor suppressor in prostate cancer cells. We identify a distinct 
mRNA signature that is enriched for MYC-regulated transcripts and transcription factor binding sites in 
USP2a overexpressing prostate cancer cells. We demonstrate that these genes are associated with an 
invasive phenotype in human prostate cancer and that the proliferative and invasive properties of USP2a 
overexpressing cells are MYC-dependent. These results highlight an unrecognized mechanism of MYC 
regulation in prostate cancer and suggest alternative therapeutic strategies in targeting MYC.
SIGNIFICANCE: The deubiquitinating enzyme USP2a has previously been shown to be oncogenic, overex-
pressed in almost half of human prostate adenocarcinomas, and prolongs the half-life of targets such as 
fatty acid synthase, MDM2, and cyclin D1. Here, we highlight a new mechanism by which USP2a enhances 
MYC levels through the modulation of specific subsets of microRNAs in prostate cancer, suggesting 
alternative therapeutic strategies for targeting MYC. Cancer Discovery; 2(3);236–47. ©2012 AACR.
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multiple miRNAs and causes widespread reprogramming 
of the miRNA network, which has been found to directly 
contribute to tumorigenesis (4, 6, 16).
Deubiquitinating enzymes represent one of the largest 
families of enzymes responsible for regulating proteins 
through the ubiquitin–proteasome system (17). Specific 
deubiquitinating enzymes regulate the stability and func-
tion of critical cellular factors such as MYC, p53, cyclin D1, 
and MDM2–MDMX (7, 18–21). Ubiquitin-specific prote-
ase 2a (USP2a) is a deubiquitinating enzyme that regulates 
the p53 pathway by targeting MDM2 (22). It also recog-
nizes fatty acid synthase and cyclin D1 and modulates and 
prevents their proteasomal degradation (21–23). USP2a is 
overexpressed in almost half of human prostate adeno-
carcinomas, enhances tumorigenicity of prostate cancer 
cells in vitro and in vivo, and confers resistance to apoptosis 
induced by chemotherapeutic agents (24). Here we show 
that USP2a mediates suppression of the miRNA cluster 
miR-34b/c and that the consequent upregulation of MYC 
is critical for the tumorigenic potential of prostate cancer 
cells. Importantly, we show that overexpression of USP2a 
and downregulation of its target miR-34a/b through the 
modulation of the MDM2–p53 axis are associated with an 
invasive phenotype in prostate tumor cells. This is the first 
example of a mechanistic link between deubiquitination 
and miRNA expression, which in turn impacts the activ-
ity of MYC. These findings suggest that MYC, a driver of 
as many as one third of human prostate cancers, may be 
targeted by USP2a or miR-34b/c.
INTRODUCTION
The c-myc proto-oncogene is a transcription factor that 
plays a key role in regulating numerous cellular processes 
including metabolism, development, apoptosis, cell pro-
liferation, and differentiation. Deregulated expression of 
MYC has been described in many human malignancies (in-
cluding colon, breast, and prostate cancer) and plays a cen-
tral role in their genesis (1). In prostate cancer, MYC seems 
to be a key player in disease progression and the presence 
of myc gene amplification (in up to 30% of cases) is associ-
ated with advanced histologic grade and worse prognosis 
(2). Transgenic mice expressing human MYC in the mouse 
prostate develop murine prostatic intraepithelial neopla-
sia followed by invasive adenocarcinoma and display a de-
fined myc gene expression signature (3). Transcriptional 
regulation, posttranscriptional regulation, and ubiqui-
tination appear to be important nodes in this MYC-driven 
network (4–8).
MicroRNAs (miRNAs) are evolutionarily conserved, 
endogenous, small noncoding RNAs that act as post-
transcriptional regulators of gene expression. They primar-
ily bind to the 3′UTR of target transcripts leading to mRNA 
degradation or translational repression. Aberrant expres-
sion of miRNAs has been observed in human cancers (9, 
10), where they can function as either tumor suppressor 
genes or oncogenes (11). Regulation of gene activity by mi-
RNAs is critical to both normal cellular function and tu-
morigenesis. Recent studies have identified several miRNAs 
as regulators of MYC (12–15). Conversely, MYC regulates 
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observed in iPrEC, transfection with exogenous USP2aWT trig-
gers downregulation of miR-34b/c, miR-98, and let-7c expres-
sion levels, whereas miR-18a, 19a, and 20a are significantly 
induced when compared with USP2aMUT and empty vector 
controls (Fig. 1C). Conversely, siRNA-mediated inhibition of 
endogenous USP2a expression increases miR-34b/c, miR-98, 
and let-7c expression by approximately 5-fold (Fig. 1D).
USP2aWT-Deregulated miRNAs Lead to Increased 
MYC Expression
In silico predictive models indicate that the whole set of 
USP2a-downregulated miRNAs potentially target c-myc 
(Supplementary Fig. S2). To verify whether MYC levels are 
actually affected by USP2a activity, we assayed c-Myc pro-
tein levels in control, USP2aWT, and USP2aMUT iPrEC cells. 
Figure 2A shows that overexpression of USP2aWT, but not 
RESULTS
USP2a Overexpression Downregulates miR-34b/c 
in Prostate Cells
To assess alterations in miRNA expression associated with 
USP2a overexpression, a curated set of prostate-specific mi-
RNAs (n = 51) (10, 25, 26) was quantitated after overexpres-
sion of either USP2aWT or USP2aMUT (C276A and H549R) in 
immortalized prostate epithelial cells (iPrEC) (24, 27) (Fig. 
1A). iPrEC–USP2aWT cells exhibit an altered miRNA expres-
sion profile relative to the empty vector control and iPrEC–
USP2aMUT (Fig. 1B and Supplementary Fig. S1) characterized 
by significant and WT-specific downregulation of miR-98, the 
miR-34b/c cluster, and Let-7c and upregulation of miR-18a, 
miR-19a, and miR-20a. To validate the miRNA signature in 
cancer cells, the USP2aWT-deregulated miRNAs were quantified 
in the androgen dependent prostate cancer cell line LNCaP. As 
Figure 1.  USP2a overexpression modifies the microRNA expression profile of prostate cells. A, analysis of USP2a mRNA and protein expression 
in empty vector (Vector), USP2aMUT, and USP2aWT iPrEC transfectants. B, prostate-specific microRNA expression profiling color heat-map carried out 
by TaqMan quantitative reverse-transcription PCR assay in the indicated iPrEC cells. Evaluation of USP2a protein expression and microRNA level 
analysis performed in LNCaP cells on (C) transfection with empty vehicle (Ve), pCDNA3 (Vector), pUSP2aMUT, or pUSP2aWT; and (D) incubation with 
empty vehicle (Ve), control (siControl), or specific USP2a (siUSP2a) silencing oligonucleotides. All data represent mean ± standard deviation of at 
least three independent replicates. P values: *P < 0.05, **P < 0.01, ***P < 0.001. See also Supplementary Figure S1. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; WB, Western blot.
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invasive prostate cancer, decreasing expression levels of hsa-
miR-34b and hsa-miR-34c-5p are significantly associated with 
increasing MYC expression (both by t test and linear regression 
analyses; Supplementary Fig. S6).
Together these results strongly suggest that the increase in 
MYC protein caused by USP2a overexpression is mediated by 
the suppression of miR-34b/c. Thus, the c-myc transcript is 
directly targeted by the miR-34b/c cluster.
USP2a Regulates the miR-34b/c Cluster by 
Directly Impairing the MDM2–p53 Pathway
p53-mediated regulation of miR-34b/c and p53 binding 
sites in the miR-34b/c promoter region have been previously 
reported (26, 30, 31). In addition, the miR-34 family including 
miR-34b/c is regulated by p53 in ovarian tumors (26). However, 
because miRNAs are both temporal and spatial in their expres-
sion, we sought to verify through chromatin immunoprecipita-
tion (ChIP) whether the p53 protein actually binds to the p53 
putative binding sites (RE1 and RE2 regions) of the miR-34b/c 
promoter in prostate cancer cells. The human miR34b/c regula-
tory region was virtually divided into overlapping fragments 
(regions from A to O; Fig. 3A) and amplified in ChIP assays by 
specific oligonucleotide pairs in LNCaP cells. Figure 3B shows 
that the p53 transcription factor is recruited to the miR34b/c 
promoter in LNCaP cells, where it exclusively binds to the pre-
dicted RE2 region (fragment F) in a transcriptionally active 
status. The specificity of p53 binding to the miR-34b/c pro-
moter was confirmed by ChIP after endogenous p53 silencing 
(Supplementary Fig. S7A), which was responsible for decreased 
miR-34b and miR-34c expression and associated with a down-
stream increase of MYC protein level (Supplementary Fig. S7B).
USP2a has been previously reported to directly bind and sta-
bilize MDM2 (22). We therefore hypothesized that MDM2 can 
mediate the USP2a-driven regulation of miR34b/c cluster ex-
pression. As expected, we observed that USP2a levels strongly 
correlated with cellular levels of MDM2 (Supplementary Fig. 
S8). We next set out to demonstrate that altered MDM2 pro-
tein expression is responsible for the USP2a-driven regula-
tion of miR-34b/c cluster expression in LNCaP cells (Fig. 3C). 
Indeed, ectopic induction of MDM2 reduces the expression of 
the miR-34b/c cluster. Similarly, MDM2 silencing triggers the 
overexpression of miR-34b/c (Fig. 3C). These results are sup-
ported by ChIP results that clearly demonstrate reduced p53 
binding to the RE2 sequence (as seen with USP2aWT overex-
pression) in cells overexpressing MDM2 (Fig. 3D). Conversely, 
small intefering RNA-mediated silencing of MDM2 in the 
USP2aWT clone activates p53 and enhances its downstream 
recruitment to both the RE1 and RE2 containing sequences 
(Fig. 3D). Furthermore, treatment with Nutlin-3a (a specific 
MDM2 inhibitor) leads to dose-dependent activation of p53 
in LNCaP cells with resultant upregulation of miR-34b/c and 
downregulation of MYC (Fig. 3E). Different p53 putative bind-
ing boxes have also been identified along the 5′ upstream re-
gions (up to 50 kb) of both the miR-98 and let-7c genomic 
loci (Supplementary Fig. S9A). Both miRs are modulated by 
USP2aWT and are directly involved in the USP2a-mediated 
modulation of MYC expression; however, miR-98 and let-7c 
are not regulated by p53 in prostate cancer cells. In fact, di-
rect and USP2a-mediated p53 inhibition (Supplementary 
Fig. S9B) together with siUSP2a and Nutlin-mediated p53 in-
duction (Supplementary Fig. S9C) are both unable to affect 
USP2aMUT, enhances MYC protein expression approximately 
4-fold compared with parental cells (upper panel) and a cor-
responding increase in MYC-specific transcription target gene 
expression (Fig. 2A, bottom panel). However, if MYC is silenced 
in USP2aWT iPrEC cells (Fig. 2B), its target gene expression (in-
cluding the MYC-regulated oncogenic miR-17-5p cluster, miR-
18a, miR-19a, and miR-20a) (6) is only partially silenced. This is 
also applicable to other experimental models, because a dose–
response induction of USP2aWT, but not USP2aMUT, in LNCaP 
cells triggers the progressive upregulation of MYC along with 
the subset of MYC canonical target genes (Supplementary Fig. 
S3A). Indeed, MYC silencing in USP2aWT-overexpressing trans-
fectants partially reverts the USP2a-induced upregulation of 
the oncogenic miR-17-5p cluster expression (Supplementary 
Fig. S3B), similar to what is observed in primary iPrEC cells. 
The predicted annealing of miR-34b/c, miR-98, and let-7c 
to the 3′UTR of the human c-myc transcript is schematized in 
Supplementary Figure S4A. Regulation of MYC by the miR-
98/Let-7 family has previously been described (15), and both 
miR-98 and let-7c overexpression are able to reverse USP2a-
driven MYC induction (Supplementary Fig. S4B). We then 
focused on MYC regulation by the miR-34b/c cluster. We 
first assessed whether MYC upregulation was dependent on 
miR-34-b/c deregulation in iPrEC cells. Exogenous adminis-
tration of increasing concentrations of synthetic miR-34b or 
miR-34c molecules enhances miR-34b and miR-34c levels in 
a dose-dependent manner (Fig. 2C) while progressively down-
regulating MYC protein expression (Fig. 2D). To determine 
whether this effect was direct, we assayed luciferase (LUC) re-
porter gene expression in iPrEC cells transfected with a pGL3-
promoter vector carrying the c-myc 3′UTR cloned downstream 
of the LUC stop codon (28). The relative LUC activity levels 
were comparable in control and USP2aMUT iPrEC clones but 
increase by approximately 6-fold in USP2aWT iPrEC cells (Fig. 
2E); moreover, in wild-type cells, the high reporter gene activ-
ity is repressed in a dose-dependent manner after overexpres-
sion of either miR-34b or miR-34c (Fig. 2E). Consistent with 
the iPrEC data, when USP2aWT-expressing LNCaP cells are 
transfected with exogenous miR-34b/c, MYC protein expres-
sion is impaired (Supplementary Fig. S5A). Similarly, MYC 
protein is depleted by USP2a silencing (siUSP2a) in LNCaP 
cells (Supplementary Fig. S5B, top panel) and restored by 
miR34b/c knockdown in infected cells (Supplementary 
Fig. S5B, bottom panel).
To verify whether the c-myc transcript is a direct target of 
USP2a-regulated miRNAs, a miR-IP assay was performed. 
Cells were cotransfected with expression vectors for HA-tagged 
AGO1 and the indicated miRNA mimics molecules (Fig. 2F). 
The immunoprecipitated RNA was analyzed by quantitative re-
verse transcription–PCR (qRT-PCR) using specfic primers for 
c-myc and normalized to 5S rRNA. miR-98 and let7c were in-
cluded as c-myc–targeting positive controls. Relative to input, 
c-myc was significantly (P < 0.002) enriched in the pulldown 
with miR-34b and miR-34c, thus demonstrating that c-myc 
mRNA is directly targeted by the miR-34 cluster. To further 
confirm the inverse relationship between MYC and miRNA ex-
pression, we queried the NCBI Gene Expression Omnibus data-
base and identified two data sets in which measurements from 
the same patients were obtained for both mRNA and miRNA 
expression [GSE21034 and GSE21036 (29)]. Our analysis con-
firmed that on progression from a normal prostate to locally 
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Figure 2. USP2a-dependent miRs deregulation modulates MYC expression. 
A, Western blot analysis of MYC protein level and evaluation of MYC specific 
transcription target genes carried out in USP2a overexpressing immortalized  
prostate epithelial cells (iPrEC) cells. B, evaluation of MYC protein level (left panel), 
MYC–regulated transcripts, and microRNAs (right panels) performed in empty vector 
iPrEC cells (Vector) and iPrEC–USP2aWT cells silenced for either green fluorescent 
protein or MYC expression. Analysis of miR-34b and miR-34c (C) and MYC expression 
levels (D) in iPrEC–USP2aWT cells after treatment with increasing concentrations of 
control (CTR), miR-34b, and miR-34c synthetic molecules. E, luciferase (LUC) reporter 
assay performed in empty vector (Vector), USP2aMUT, and USP2aWT iPrEC transfectants 
(top panel) and in USP2aWT iPrEC clone exposed to increasing concentrations of control 
(CTR), miR34b, and miR-34c synthetic molecules (bottom panel). F, isolation of target 
transcripts associated with miR-34b/c. Cells were cotransfected with expression 
vectors for HA-tagged AGO1 and the indicated microRNA mimics and a control mimic. 
The immunoprecipitated RNA was analyzed by qRT-PCR using specific primers for myc 
and normalized to 5S rRNA and immunoprecipitate from control mimic. miR-98 and 
let7c, which are known to target c-myc, served as controls. Relative to input, c-myc was 
significantly (P < 0.002) enriched in the pulldown with miR-34b and miR-34c. All data 
represent mean ± standard deviation of at least 3 independent replicates. P values: 
*P < 0.05, **P < 0.01, ***P < 0.001. See also Supplementary Figures S2 to S5. WB, 
Western blot.
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mutants (Δ13-19 or 22Gln/23Ser) and USP2a coexpression 
lead to an upregulation of MYC expression (data not shown). 
Taken together, these results suggest that USP2a regulates 
MYC expression through the MDM2–p53 axis. 
mRNA Signature of USP2a-Overexpressing Cells
To characterize the molecular signature associated with 
USP2a overexpression, we next analyzed differential gene ex-
pression in iPrEC transfected with USP2aWT and USP2aMUT 
using the Affymetrix Human Genome U133 Plus 2.0 Array 
(Fig. 5). Empty vector was used as a control (EV). Direct com-
parison of the three distinct groups of samples (WT, MUT, 
EV) revealed robust differential expression of distinct sets of 
genes and cellular pathways associated with the expression of 
USP2aWT. A total of 789 genes were differentially expressed be-
tween USP2aWT and USP2aMUT; 848 genes were differentially ex-
pressed between USP2aWT and EV; 54 genes were differentially 
expressed between USP2aMUT and EV (P < 0.0001 after adjust-
ment for multiple testing in all pairwise comparisons). USP2a 
overexpression was associated with a global gene expression 
upregulation, and mRNA transcripts for several cancer-related 
genes such as c-myc were more highly expressed in the USP2aWT 
miR-98/let-7c expression or trigger p53 recruitment to its 
response elements in miR regulatory regions in LNCaP cells 
(Supplementary Fig. S9D). Our data suggest that, in prostate 
cancer cells, USP2a-mediated induction of MDM2 and sub-
sequent degradation of p53 impedes the transcription of the 
miR-34b/c miRNA cluster.
To verify the biochemical effect of USP2a expression on the 
MDM2–p53 pathway and the subsequent impact on MYC 
protein expression, we carried out a time-course experiment 
to measure the levels of USP2a, MDM2, p53, and MYC and 
miR-34b/c at different points after USP2aWT overexpression 
in LNCaP cells (Fig. 4). USP2a expression is first detectable 
at 12 hours posttransfection and is sustained during the first 
36 hours. Subsequently, MDM2 is upregulated (24–36 hours 
posttransfection) and p53 is downregulated (36–60 hours 
posttransfection). Although the decrease in miR-34b/c expres-
sion occurs as early as 12 hours after USP2a transfection, the 
final effect on MYC overexpression is evident after 60 to 72 
hours. We confirmed these results by using a prostate cell line 
(PC3) devoid of p53. When we restore wild-type p53 presence 
under USP2a expression, we observe a decrease in MYC ex-
pression similar to LNCaP. Conversely, nondegradable p53 
 Figure 3.  A, schematic representation of the genomic region mapping 4 Kb upstream of the miR-34b/c cluster site on chromosome 11 (position 
11q23.1: [110,888,873–110,889,450]). DNA fragments amplified by each oligonucleotide pair are represented by arrows (A–O). B, ChIP assay of LNCaP 
cells with immunoprecipitation of chromatin without antibody (no Ab) and with specific anti-p53, p300, AcH4, phosphorylated Pol-II, or control 
immunoglobulin G (IgG) antibodies. PCR amplification of amplicons A–O on the putative miR34b/c regulatory region, on the p21 promoter (positive 
control), and on the cyclin B1 intron (negative control) are highlighted. C, Western blot evaluation of MDM2 (top panel) and microRNA 34b/c expression 
analysis (bottom panel) carried out in LNCaP cells after transient transfection with empty vector (Vector), pMDM2 expression vector, and in USP2aWT_
LNCaP transfectants silenced with either control (siGFP) or specific MDM2 siRNAs. D, p53-ChIP assay (as described in B, top panels) and evaluation of 
MYC protein levels (bottom blots) performed in LNCaP cells after transient transfection with empty vector (Vector), pMDM2 expression vector, and in 
USP2aWT–LNCaP transfectants silenced with either control (silenced green fluorescent protein) or specific MDM2 siRNAs. E, Western blot of p53 and 
MYC protein levels (top panel) and miR-34b and miR-34c expression levels (bottom panel) carried out in LNCaP cells treated with increasing 
concentrations of Nutlin-3a in dimethyl sulfoxide. All histograms represent mean ± standard deviation of at least three independent replicates. 
P values: *P < 0.05, **P < 0.01, ***P < 0.001.
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stromal compartment. Interestingly, USP2aWT genes appeared 
to be strongly upregulated during local invasion of cancer cells, 
because they were most strongly enriched when locally invasive 
cancers were compared with prostatic intraepithelial neoplasia 
specimens (Fig. 5C).
Targeting MYC in USP2a-Overexpressing Cells 
Suppresses Growth and Invasion
USP2a modulation of MYC protein expression may have 
important biologic implications for the natural history of 
prostate cancer. We demonstrate that the proliferative capac-
ity, cell viability, and clonogenic ability of LNCaP USP2aWT 
cells can be significantly impaired by targeting MYC expres-
sion. This can be achieved by direct silencing of MYC, by ad-
ministration of Nutlin-3a, or by treating USP2aWT cells with 
synthetic miR-34b/c molecules (Supplementary Fig. S12).
Because enrichment of the genes upregulated by USP2AWT is 
observed during local invasion of prostate cancer (Fig. 5C), we 
next analyzed publicly available gene expression profiles of a 
number of distinct cancer invasion models. CAT-plot analysis 
revealed significant agreement between genes upregulated by 
USP2aWT and those upregulated on invasion in each model 
considered (P < 0.001). The strongest agreement was observed 
with migration efficiency/velocity in Boyden chamber as-
says using cell lines from prostate and other cancers (Fig. 6). 
Interestingly, in the prostasphere invasion model, the strongest 
agreement was observed between the USP2a signature and the 
genes differentially expressed between the “stellate” and “mass” 
phenotypes, whereas overlap was observed when the compari-
son involved the “round/branching” noninvasive phenotypes 
(data not shown). The “stellate” phenotype corresponds to in-
vading cancer cell lines, the “mass” phenotype to noninvasive 
cancer cell lines and transformed normal prostatic epithelial 
cells, and the “round/branching” phenotype to iPrECs and non-
transformed lines. In agreement with the CAT-plot analysis, the 
group compared with either the USP2aMUT or EV cell lines. 
Complete lists of differentially expressed genes for the pairwise 
comparisons can be accessed online (32). We further show that 
the gene expression signatures USP2aMUT and EV cell lines are 
indistinguishable and differ markedly from the discrete gene 
expression signature associated with USP2aWT at both the gene 
and pathway levels [Fig. 5A; see also volcano and "correspon-
dence-at-the-top” (CAT) plots shown in Supplementary Fig. S10 
and Supplementary Fig. S11]. We next applied the one-sided 
Wilcoxon rank-sum test to investigate differential enrichment 
of 86170 functional gene sets corresponding to specific anno-
tation and biological themes in iPrEC transfected with either 
USP2aWT or USP2aMUT relative to EV control. Functional gene 
sets were retrieved from a variety of genomics databases, en-
abling the interrogation of cellular pathways, protein networks, 
transcription factors, miRNA targets, genomic locations, enzy-
matic activities, and cellular processes. This analysis indicated 
that MYC-related functional gene lists were associated with 
USP2aWT overexpression (in contrast to USP2aMUT and EV). 
Global upregulation of genes transcribed by MYC (33) and of 
miR-34c mRNA targets (34) was mirrored by the overall down-
regulation of genes repressed by p21 in a p53-dependent man-
ner (35) and targeted by miR-19a [34 (Fig. 5B)]. The complete 
thematic list and functional pathways differentially enriched 
between USP2aWT and USP2aMUT cell lines can be accessed on-
line (32). Finally, we compared both USP2aWT- and USP2aMUT-
specific gene expression signatures (i.e., the nonoverlapping 
segments of the Venn diagrams in Fig. 5A) to a large, publically 
available laser capture microdissected prostate cancer data set 
[GSE69099 data set (36); Fig. 5C]. We similarly used gene set 
analysis also to evaluate whether up- and downregulated USP2a 
gene lists were consistently enriched along prostate cancer pro-
gression. Genes upregulated on transfection of USP2aWT are 
enriched in the epithelial compartment of human prostate can-
cer, whereas genes upregulated by USP2aMUT are enriched in the 
Figure 4. USP2a regulates MYC expression through the MDM2–p53 axis. A, kinetics profile (0–72 hours) of protein levels in LNCaP cells after 
pUSP2aWT (purple bars) overexpression or empty vector (green bars). Representative blots are shown at each set point for the specific protein (upper 
panel) and actin levels (lower panel). B, miR-34b/c expression profile under the same conditions depicted in A.
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induction or repression of transcription. There are a number of 
molecular mechanisms hypothesized for the oncogenic func-
tion of MYC (1, 37–40). Importantly, this study highlights a 
previously unrecognized mechanism of MYC regulation es-
tablishing a novel link between deubiquitination, miRNA de-
regulation, and the p53/MYC regulatory network. Gene set 
enrichment analysis of microarray expression in human tumors 
highlights a MYC-related gene set supporting the link between 
USP2a and MYC. Indeed, the MYC-related gene set associated 
with USP2aWT overexpression is differentially expressed between 
cancer and the normal prostate and, importantly, these genes 
are associated with prostate tumor progression. Specifically, we 
show that the proliferative capacity, cell viability, clonogenic 
ability, and invasive properties of USP2aWT overexpressing cells 
can be significantly impaired by targeting MYC expression. 
Although novel therapeutics to target MYC-dependent tumors 
have been developed (41–43), these are generally not effective. 
This study provides evidence that, at least in prostate cancer, 
MYC may be affected by targeting either USP2a or MDM2.
Although studies addressing the role of miRNAs in cancer 
pathogenesis are at an early stage, it is clear that miRNA 
expression patterns correlate strikingly with disease progres-
sion and response to therapy (44). However, the biological 
roles of only a very limited number of miRNAs have been 
in vitro invasion test demonstrates that UPS2aWT overexpres-
sion increases the invasive ability of iPrEC when compared with 
control or USP2aMUT-transfected cells, and, when silenced in an 
LNCaP experimental model, reduces invasion by almost 2-fold 
(Fig. 6C). miR-34b/c seems to be involved in the USP2a-
mediated invasiveness, because modulation of their expression 
by either mimic treatment in iPrEC–USP2aWT cells or by an-
tago-miR addition to USP2a-silenced LNCaP cells is able to sig-
nificantly affect the relative prostate invasive ability (Fig. 6C).
DISCUSSION
Deubiquitinating enzymes can prevent destruction of pro-
tein substrates before proteosomal degradation. USP2a deu-
biquitinates the antiapoptotic proteins fatty acid synthase, 
the ubiquitin ligase MDM2, and cyclin D1. USP2a is overex-
pressed in approximately 40% of human prostate adenocarci-
nomas (24) and exhibits oncogenic behavior both in vitro and 
in vivo. In addition, USP2a silencing in several human cancer 
cell lines results in apoptosis.
Oncogenic activation of c-myc is one of the most frequent 
events in human malignancy in general and prostate cancer in 
particular. c-myc is a master regulatory gene that can globally 
reprogram cells to proliferate or undergo apoptosis through 
Figure 5. USP2a overexpression is associated with a discrete mRNA signature that is enriched for MYC-regulated transcripts. A, Venn diagram of 
differentially expressed genes in immortalized prostate epithelial cells (iPrEC) transfected with USP2aWT and USP2aMUT and empty vector (EV) control. 
Nominal adjusted P value < 0.0001; results are for all nonredundant NCBI ENTREZ Gene identifiers available on Affymetrix U133 Plus 2.0 Array. Red, 
upregulated genes; green, downregulated genes. B, functional annotation analysis for genes differentially expressed between USP2aWT and USP2aMUT. 
Genes were ordered by moderated t-statistics obtained from USP2aWT and USP2aMUT contrast, whereas functional gene sets were obtained from different 
databases (see Supplementary Microarray Methods and Results sections). K5Z233–V–MYCMAX–01 and K5Z233–V–NMYC–01: genes that contain a 
transcription factor binding site (TFBS) for the heterodimer Myc-Max or n-Myc in the 10-Kb genomic region around their transcription starting site (TSS) 
with a false discovery rate (FDR) less than 1%; UNION–hsa–miR–34c and UNION–hsa–miR–19a: union sets of genes described as targets for miR-34c or 
miR19a by DIANA-microT, miRanda, TargetScanS, and PicTar, as obtained from the miRGen database (34); MYC–ONCOGENIC–SIGNATURE: cMYC target 
genes (33), functional gene sets obtained from the Molecular Signature Database (MSigDB); P21–P53–ANY–DN: p21 downregulated (p53-dependent) 
genes (33), functional gene sets from the MSigDB; YU–CMYC–UP: c-Myc target genes in a p53-null background, functional gene sets from the MSigDB. 
Analysis of functional annotation revealed gene set enrichment for upregulation of MYC and miR-34c target genes and gene set enrichment for 
downregulation of p21-p53 and miR-19a target genes. Color values represent absolute log10 adjusted P values resulting from the Wilcoxon rank-sum test 
after multiple testing correction. Orange/red boxes show concordant upregulation, whereas blue boxes show concordant downregulation. C, enrichment 
analysis of genes up- and downregulated in USP2aWT and USP2aMUT in sequential transitions along human prostate cancer progression as analyzed in the 
GSE6099 data set (36). The following transitions were considered: Neoplasia: prostatic intraepithelial neoplasia epithelial cells versus NORMAL epithelial 
cells; Cancer: prostatic intraepithelial neoplasia and prostate cancer epithelial cells versus NORMAL epithelial cells; Invasion: prostate cancer epithelial 
cells versus prostatic intraepithelial neoplasia epithelial cells; Gleason: high Gleason (, 7) prostate cancer epithelial cells versus low Gleason (. 7) 
prostate cancer epithelial cells; Progression: metastatic prostate cancer epithelial cells versus locally invasive prostate cancer epithelial cells; AR 
independence: androgen-resistant metastatic prostate cancer epithelial cells versus androgen-naive metastatic prostate cancer epithelial cells; Epi 
versus Stro: laser capture-microdissected epithelial cells versus laser capture-microdissected stromal cells; Stro prostate cancer versus Stro NOR: laser 
capture-microdissected from stromal cells adjacent to prostate cancer versus laser capture-microdissected stromal cells from normal prostate. Color 
values represent absolute log10 P values resulting from the Wilcoxon rank-sum test. Orange/red boxes show concordant upregulation, whereas blue boxes 
show concordant downregulation. See also Supplementary Figures S9 and S10.
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Figure 6. USP2a overexpression 
increases the invasive ability of prostate 
cells. CAT plot showing the agreement 
between USP2a and invasion gene 
expression signatures. Genes upregulated 
by wild-type USP2a transfection as 
compared with mutant USP2a showed 
significant overlap with genes expressed 
on invasion in a number of distinct 
laboratory models. On the y-axis is shown 
the proportion of genes in common; on the 
x-axis is shown the number of top ranking 
genes considered. The black line 
corresponds to proportions of common 
genes by chance; gray shades around this 
black line correspond to decreasing 
probabilities of agreement by chance 
(0.05, 0.01, and 0.001). Therefore, CAT 
curves in the top white area of the graph 
have a probability of agreeing by chance 
of P < 1E-03. In the figure, genes were 
ranked by decreasing t-statistic as 
obtained from our linear model analysis. 
Each line represents a different pairwise 
comparison between differential gene 
expression between wild-type and mutant 
USP2a compared with differential gene 
expression between: A, (A) fast and slow 
migrating cell lines from various cancer 
types in Boyden assays (red line); (B) fast 
(PC3) and slow (LNCaP) migrating 
prostate cancer (PCA) cell lines in Boyden 
assays (blue line); (C) mouse male and 
female urogenital sinuses at gestational 
day 17 (± 0.5) (green line); (D) Matrigel 
invasive and noninvasive prostaspheres 
(purple line); (E) laser capture 
microdissected epithelial cells from 
locally invasive prostate cancer and 
prostatic intraepithelial neoplasia (PIN) 
(orange line); B, (A) fast and slow migrating 
cell lines from various cancer types in 
Boyden assays (red line); (B) fast (PC3) and 
slow (LNCaP) migrating prostate cancer 
cell lines in Boyden assays (blue line); (C) 
mouse male and female urogenital sinuses 
at gestational day 17 (± 0.5) (green line); 
(D) Matrigel invasive and noninvasive 
prostaspheres (purple line); C, evaluation 
of relative invasive ability performed in 
iPrEC clones and in LNCaP cells by 
ECMatrixTM Invasion Chamber. The 
iPrEC–USP2aWT transfectant has been 
also treated with miR synthetic molecules 
(mimic), whereas USP2a-silenced LNCaP 
cells underwent further treatment with 
specific antagomirs (KO molecules) before 
invasion assessment. Data represent 
mean ± standard deviation of 4 
independent replicates. P values: *P < 
0.05, **P < 0.01.
elucidated in cancer cells. The downregulation of miR-34b/c 
expression that results from USP2a overexpression suggests 
a direct role of the miR-34b/c cluster as a potential tumor 
suppressor in prostate cancer. Furthermore, the regulation 
of miRNAs by USP2aWT is the first example of the ubiquitin–
proteasome pathway playing a role in miRNA biology. We 
outline our proposed model for this mechanism in Figure 7.
Several studies have demonstrated the use of developing spe-
cific inhibitors of ubiquitin ligases and deubiquitinating enzymes 
as valuable therapeutic strategies against cancer (45, 46). Our 
results further underscore the importance of these therapeutic 
strategies and suggest that USP2a inhibitors may offer a poten-
tially viable means of targeting MYC-dependent prostate cancer.
METHODS
Cell Culture
Empty vector (Vector), wild-type (USP2aWT), and mutant 
(USP2aMUT) stable clones (previously established by infecting 
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transcript expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase levels. qRT-PCR was carried out with 1 μL of cDNA 
using SYBR Green master mix (Applied Biosystems) and analyzed 
on a StepOne Plus Real Time PCR Detection System (Applied 
Biosystems). All reactions were run in triplicate and the relative 
abundance of specific mRNA levels was calculated by normalizing 
to both glyceraldehyde-3-phosphate dehydrogenase and aldolase A 
expression using the 2-ΔΔCt method (47). All sequences of oligonucle-
otide primers are reported in Supplementary Tables S2–3.
Immunoprecipitation of miRNA Targets
PC3 cells (0.5 × 106 cells) were cotransfected with 1 μg of HA-
AGO1 (pIRES-FLAG/HA vector; Addgene) and 50 nM of miRNA 
mimics using Lipofectamine 2000 (Invitrogen). After 2 days, cells 
were harvested using 400 μL lysis buffer (100 mM KCl, 5 mM MgCl2, 
10 mM HEPES, pH 7.0, 0.5% Nonidet P-40) containing freshly added 
RNaseOUT (Invitrogen) and Protease Inhibitor Cocktail (Roche). 
After centrifugation, a 50-μL aliquot of supernatant was taken as 
input for subsequent RNA extraction. The remaining supernatant 
was gently shaken with HA-beads (HA-probe Santa Cruz sc-7392) for 
4 hours at 40°C in Spin Columns-Screw Cap (Pierce). The columns 
were drained, washed, and the retained beads were treated with 5 U 
DNaseI in NT2 buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 0.05% Nonidet P-40) for 10 minutes at 37°C, washed with 
NT2, and then treated with Proteinase K in NT2 plus 1% sodium 
dodecyl sulphate for 30 minutes at 55°C. Finally the beads were re-
suspended in NT2 buffer and RNA was extracted using acid phenol-
choloroform (Ambion-Applied Biosystems) to extract RNA. RNA was 
reverse-transcribed and analyzed with quantitative PCR for enrich-
ment of c-myc mRNA.
Chromatin Immunoprecipitation Assay
Cells were washed with phosphate-buffered saline (supplemented 
with phosphatase inhibitors) and incubated for 10 minutes with 1% 
formaldehyde at room temperature. Formaldehyde crosslinking was 
stopped by adding glycine, pH 2.5 (125 mM final concentration), for 
5 minutes at room temperature. Cells were scraped off the plates, ly-
sated in sodium dodecyl sulphate lysis buffer (1% sodium dodecyl 
sulphate, 10 mM EDTA, 50 mM Tris-HCl, pH 8, plus protease in-
hibitor mixture), and sonicated to generate 500- to 2000-bp fragments. 
After centrifugation, the supernatant was diluted 10-fold in immu-
noprecipitation buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 5 MM 
EDTA, 0.5% Nonidet P-40) and incubated at 4°C with Protein A/G 
beads (Pierce) (previously adsorbed with sonicated single-stranded 
DNA and bovine serum albumin). The cleared lysate was incubated 
iPrEC [23, 24] were grown in specific PrEBM medium; Cambrex) 
and selected in 1.6 μg/mL puromycin. Human prostate adenocar-
cinoma LNCaP and PC3 cells were obtained from the American 
Type Culture Collection (ATCC) and grown in RPMI-1640 medium 
(Invitrogen, Life Technologies) containing 10% fetal bovine serum 
(GIBCO-Invitrogen) and 1% penicillin–streptomycin (Invitrogen). 
Cell lines were purchased from ATCC in 2006. Both LNCaP and 
PC3 cells have been periodically tested (every 3 months) for cell 
morphology, growth rate, colony-forming ability, and gene expres-
sion of both p53 and AR. Moreover, cells have undergone a con-
tamination test for excluding mycoplasma presence by Hoechst 
staining and PCR-based exogenous DNA detection.
Cell Transfection and Luciferase Reporter Assay
Transient transfection experiments were carried out by seed-
ing cells in 60-mm Petri dishes in complete medium (2 × 105 cells/
plate). Transfection was performed 24 hours after plating using 
Lipofectamine 2000 reagent in Optimem medium (Invitrogen) for 
siRNA oligonucleotides (100–500 nM) and synthetic/knockdown miR 
molecules (10–50 nM) and by JetPei reagent (PloyPlus-Transfection) in 
complete medium for expression vectors (0.5–5 μg) and LUC-reporter 
plasmids. Evaluation of protein, mRNA, and miRNA expression levels 
was performed by harvesting cells at 24-hour intervals (24–120 hours) 
after transfection. For LUC reporter assays, cells were cotransfected 
with the pGL3-myc UTR vector (1 μg) and PEQ-176 (expressing the 
control β-galactosidase enzyme, 1 μg); scrambled (CTR), or increasing 
concentrations of synthetic miR sequences were added to the transfec-
tion mix for iPrEC–USP2aWT cells. Forty-eight to 96 hours later, cells 
were rinsed with cold phosphate-buffered saline, resuspended in cell 
lysis buffer (Promega), and incubated for 10 minutes at room tem-
perature. Insoluble material was spun down, and LUC activity was 
quantified by a commercially available kit (Promega) on a TD-20E 
luminometer (Turner Biosystems). Luciferase values were normalized 
to protein contents and β-galactosidase expression. All sequences of 
siRNA are reported in Supplementary Table S1.
Western Blot
Cell lysis was performed on ice for 30 minutes in RIPA buffer (50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium de-
oxycholate, 1 mM EDTA) supplemented with phosphatase inhibi-
tors (1 mM PMSF, 1 μg/mL aprotinin, leupeptin, pepstatin). Equal 
amounts of total protein extracts (20–80 μg) were resolved by 10%, 
12%, or 15% denaturing sodium dodecyl sulphate–polyacrylamide 
gel electrophoresis and transferred for 4 hours to polyvinylidene 
difluoride membrane. Membranes were blocked in 5% milk–phos-
phate-buffered saline–0.05% Tween 20 for 1 hour and incubated 
overnight with the specific primary antibodies. Secondary antibod-
ies were horseradish peroxidase-conjugated (Santa Cruz), and ECL 
reagent (Amersham, GE Healthcare) was used for chemolumines-
cence detection.
RNA Isolation and qRT-PCR for mRNA Analysis
Total RNA was extracted using Trizol Reagent (Invitrogen). RNA 
quantity and integrity were assessed using a NanoDrop Spectro-
photometer (Thermo Scientific) and an Agilent 2100 Bioanalyzer 
(Agilent Technologies), respectively. For cDNA synthesis, 2 μg 
of total RNA was reverse-transcribed with random primers by a 
Moloney murine leukemia virus reverse transcriptase kit (M-MLV 
RT kit; Invitrogen), according to the manufacturer’s instruc-
tions. Semiquantitative RT-PCR was performed with the Applied 
Biosystems Taq enzyme (Applied Biosystems by Life Technologies) 
using 2 μL of cDNA. Polymerase chain reaction conditions were 
as follows: one cycle at 94°C (5 minutes); 23–35 cycles at 94°C (30 
seconds), 58°C (40 seconds), 72°C (40 seconds); and one cycle at 
72°C (7 minutes). Polymerase chain reaction products were run 
on a 2% agarose gel and visualized with ethidium bromide. Gene 
Figure 7. Proposed model of how USP2a-driven microRNA 
deregulation enhances MYC protein expression through impairment  
of the MDM2–p53 pathway. p53 regulates miR-34b/c expression 
through promoter enhancement. A, when overexpressed, USP2a 
transcriptionally downregulates miR-34b/c with subsequent MYC 
activation through MDM2-mediated p53 inactivation. B, low USP2a 
expression triggers the upregulation of miR-34b/c with subsequent 
MYC deactivation through MDM2-mediated p53 activation.
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Analysis of mRNA Signature of Distinct Cancer  
Invasion Models
For migration efficiency/velocity in Boyden assays, on a review of 
the literature (see supplementary references) we identified a number 
of cell lines from various cancer types displaying extreme differences in 
migration efficiency/velocity as assayed in Boyden assays, as reported 
in Supplementary Tables S8–10, and retrieved the corresponding 
Affymetrix raw gene expression data from the NCBI GEO database. 
Using the same generalized linear model approach applied to analyze 
gene expression on USP2a transfection, we analyzed differential gene 
expression between fast- and slow-migrating prostate cancer cell lines 
(PC3 and LNCaP, respectively) (Supplementary Table S9). Similarly, to 
avoid confounding with experimental batch and cell lines characteris-
tics (i.e., androgen sensitivity), we also analyzed migration efficiency/ve-
locity in Boyden assays in a balanced compounded data set accounting 
for several cancer cell lines of different tissue origin) (Supplementary 
Table S10). For three-dimensional model of prostate cancer invasion, 
we also analyzed differential gene expression associated with prosta-
spheres displaying distinct patterns of invasion in Matrigel. To this end 
we retrieved and analyzed gene expression data from the GSE19426 
series (1) comparing prostaspheres with distinct growth and invasion 
behavior (“round,” “branching,” “mass,” and “stellate,” as described by 
Harma and colleagues [see supplementary references]) using a general-
ized linear model approach as applied to analyze gene expression on 
USP2a transfection. A description of the phenotypic groups compared 
is available in Supplementary Table S11. For prostate gland branch-
ing morphogenesis, the gene expression signature of prostate gland 
branching morphogenesis was obtained by comparing mouse male and 
female urogenital sinuses at gestational day 17 (± 0.5) as analyzed in 
Schaeffer and colleagues (see supplementary references) (GSE12077).
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